



Financial Performance

Size Profile, LTM Financials, Forward Estimates

(USD in millions, except per share data)

			Size Prof	file	LTM Operati	ng Data	Forward Estimates		
Company Name	Ticker	Price at 06/30/23	% of 52 Week High	TEV	Total Assets	LTM Revenue	LTM EBITDA	2023 Est. Revenue	2023 Est. EBITDA
Healthcare Equipment and Supplies									
Medtronic plc	MDT	\$88.10	92.2%	\$127,794	\$90,948	\$31,227	\$8,376	\$32,078	\$9,160
Stryker Corporation	SYK	\$305.09	99.4%	\$120,141	\$37,409	\$19,455	\$4,794	\$20,260	\$5,295
Boston Scientific Corporation	BSX	\$54.09	98.8%	\$84,958	\$33,601	\$13,400	\$3,384	\$14,064	\$4,031
ResMed Inc.	RMD	\$218.50	88.2%	\$28,305	\$6,752	\$4,223	\$1,292	\$4,504	\$1,405
Align Technology, Inc.	ALGN	\$353.64	95.9%	\$26,732	\$6,145	\$3,737	\$714	\$3,974	\$972
The Cooper Companies, Inc.	COO	\$383.43	97.0%	\$21,192	\$11,540	\$3,427	\$840	\$3,607	\$1,076
Teleflex Incorporated	TFX	\$242.03	87.6%	\$11,920	\$6,918	\$2,860	\$781	\$2,960	\$859
Haemonetics Corporation	HAE	\$85.14	93.2%	\$5,184	\$1,935	\$1,169	\$261	\$1,249	\$342
ICU Medical, Inc.	ICUI	\$178.19	83.9%	\$4,888	\$4,463	\$2,294	\$286	\$2,261	\$393
Integra LifeSciences Holdings Corporation	IART	\$41.13	67.8%	\$4,820	\$3,778	\$1,545	\$375	\$1,555	\$387
NuVasive, Inc.	NUVA	\$41.59	76.1%	\$2,910	\$2,090	\$1,226	\$210	\$1,280	\$300

Healthcare Providers and Services										
HCA	\$303.48	99.5%	\$115,643	\$53,594	\$61,920	\$12,308	\$63,960	\$12,59 0		
CI	\$280.60	82.5%	\$108,853	\$150,054	\$186,021	\$9,860	\$191,906	\$11,758		
HUM	\$447.13	78.3%	\$57,416	\$56,455	\$98,727	\$5,161	\$103,409	\$5,803		
CNC	\$67.45	68.5%	\$39,641	\$82,853	\$138,273	\$6,315	\$147,954	\$4,897		
THC	\$81.38	95.3%	\$25,176	\$27,157	\$20,110	\$3,693	\$20,450	\$3,383		
DVA	\$100.47	97.5%	\$22,352	\$16,959	\$11,739	\$2,010	\$11,900	\$2,328		
СҮН	\$4.40	54.9%	\$13,482	\$14,648	\$12,390	\$1,244	\$12,481	\$1,513		
SEM	\$31.86	98.2%	\$8,764	\$7,702	\$6,489	\$681	\$6,622	\$812		
	CI HUM CNC THC DVA CYH	CI \$280.60 HUM \$447.13 CNC \$67.45 THC \$81.38 DVA \$100.47 CYH \$4.40	CI \$280.60 82.5% HUM \$447.13 78.3% CNC \$67.45 68.5% THC \$81.38 95.3% DVA \$100.47 97.5% CYH \$4.40 54.9%	CI \$280.60 82.5% \$108,853 HUM \$447.13 78.3% \$57,416 CNC \$67.45 68.5% \$39,641 THC \$81.38 95.3% \$25,176 DVA \$100.47 97.5% \$22,352 CYH \$4.40 54.9% \$13,482	CI \$280.60 82.5% \$108,853 \$150,054 HUM \$447.13 78.3% \$57,416 \$56,455 CNC \$67.45 68.5% \$39,641 \$82,853 THC \$81.38 95.3% \$25,176 \$27,157 DVA \$100.47 97.5% \$22,352 \$16,959 CYH \$4.40 54.9% \$13,482 \$14,648	CI \$280.60 82.5% \$108,853 \$150,054 \$186,021 HUM \$447.13 78.3% \$57,416 \$56,455 \$98,727 CNC \$67.45 68.5% \$39,641 \$82,853 \$138,273 THC \$81.38 95.3% \$25,176 \$27,157 \$20,110 DVA \$100.47 97.5% \$22,352 \$16,959 \$11,739 CYH \$4.40 54.9% \$13,482 \$14,648 \$12,390	CI \$280.60 82.5% \$108,853 \$150,054 \$186,021 \$9,860 HUM \$447.13 78.3% \$57,416 \$56,455 \$98,727 \$5,161 CNC \$67.45 68.5% \$39,641 \$82,853 \$138,273 \$6,315 THC \$81.38 95.3% \$25,176 \$27,157 \$20,110 \$3,693 DVA \$100.47 97.5% \$22,352 \$16,959 \$11,739 \$2,010 CYH \$4.40 54.9% \$13,482 \$14,648 \$12,390 \$1,244	CI \$280.60 82.5% \$108,853 \$150,054 \$186,021 \$9,860 \$191,906 HUM \$447.13 78.3% \$57,416 \$56,455 \$98,727 \$5,161 \$103,409 CNC \$67.45 68.5% \$39,641 \$82,853 \$138,273 \$6,315 \$147,954 THC \$81.38 95.3% \$25,176 \$27,157 \$20,110 \$3,693 \$20,450 DVA \$100.47 97.5% \$22,352 \$16,959 \$11,739 \$2,010 \$11,900 CYH \$4.40 54.9% \$13,482 \$14,648 \$12,390 \$1,244 \$12,481		

Financial Performance (cont.)

Size Profile, LTM Financials, Forward Estimates

(USD in millions, except per share data)

		Size Pro	file		LTM Operating Data		Forward Estimates		
Company Name	Ticker	Price at 06/30/23	% of 52 Week High	TEV	Total Assets	LTM Revenue	LTM EBITDA	2023 Est. Revenue	2023 Est. EBITDA
Pharmaceuticals									
Eli Lilly and Company	LLY	\$468.98	99.8%	\$444,847	\$53,163	\$27,691	\$9,154	\$31,477	\$10,443
AbbVie Inc.	ABBV	\$134.73	80.1%	\$317,836	\$0	\$56,023	\$28,371	\$53,210	\$25,977
Merck & Co., Inc.	MRK	\$115.39	96.4%	\$287,572	\$0	\$58,311	\$12,529	\$59,100	\$14,655
Pfizer Inc.	PFE	\$36.68	66.8%	\$217,489	\$195,617	\$92,951	\$40,637	\$66,454	\$25,448
Bristol-Myers Squibb Company	BMY	\$63.95	78.5%	\$159,079	\$93,489	\$45,187	\$18,693	\$45,395	\$19,583
Perrigo Company plc	PRGO	\$33.95	77.3%	\$8,681	\$10,955	\$4,559	\$555	\$4,825	\$728
Amneal Pharmaceuticals, Inc.	AMRX	\$3.10	83.6%	\$3,059	\$3,627	\$2,272	\$466	\$2,325	\$517

Valuation Metrics

Return Profile, Trading Multiples


			Trading Multiples						
Company Name	Ticker	Return on Assets	Return on Equity	Revenue Growth	EBITDA Margin	EBITDA Growth	5-yr Beta	TEV / LTM Revenue	TEV / LTM EBITDA
Healthcare Equipment and Supplies									
Medtronic plc	MDT	3.9%	7.2%	-1.4%	26.8%	-12.5%	0.7x	4.1x	15.3x
Stryker Corporation	SYK	6.4%	16.4%	10.4%	24.6%	5.4%	1.0x	6.2x	25.1x
Boston Scientific Corporation	BSX	4.2%	5.1%	8.7%	25.3%	10.7%	0.8x	6.3x	25.1x
ResMed Inc.	ALGN	12.2%	24.0%	18.0%	30.6%	14.7%	0.5x	6.7x	21.9x
Align Technology, Inc.	RMD	6.0%	8.7%	-6.3%	19.1%	-27.6%	1.6x	7.2x	37.5x
The Cooper Companies, Inc.	COO	2.6%	4.0%	9.2%	24.5%	-5.8%	0.9x	6.2x	25.2x
Teleflex Incorporated	TFX	5.0%	9.2%	1.5%	27.3%	-1.2%	1.0x	4.2x	15.3x
Haemonetics Corporation	IART	5.5%	14.7%	17.7%	22.3%	30.2%	0.4x	4.4x	19.9x
ICU Medical, Inc.	ICUI	0.8%	-2.3%	28.8%	12.5%	31.9%	0.6x	2.1x	17.1x
Integra LifeSciences Holdings Corporation	HAE	4.2%	7.9%	-1.4%	24.3%	-6.8%	1.2x	3.1x	12.9x
NuVasive, Inc.	NUVA	2.4%	3.3%	4.4%	17.2%	8.7%	1.1x	2.4x	13.8x
	Mean Median	4.8% 4.2%	8.9% 7.9%	8.1% 8.7%	23.1% 24.5%	4.4% 5.4%	88.9% 89.4%	4.5x 4.2x	20.4x 20.2x
Healthcare Providers and Services									
HCA Healthcare, Inc.	HCA	11.0%	N/A	3.0%	19.9%	0.3%	1.6x	1.9x	9.4x
The Cigna Group	CI	3.3%	14.8%	3.8%	5.3%	-3.7%	0.7x	0.6x	11.0x
Humana Inc.	HUM	5.8%	20.8%	9.1%	5.2%	6.0%	0.7x	0.6x	11.1x
Centene Corporation	CNC	3.7%	10.3%	7.0%	4.6%	11.6%	0.6x	0.3x	6.3x
Tenet Healthcare Corporation	DVA	6.6%	24.8%	3.9%	18.4%	2.8%	2.1x	1.3x	6.8x
DaVita Inc.	THC	4.6%	29.0%	1.0%	17.1%	-12.5%	0.9x	1.9x	11.1x
Community Health Systems, Inc.	СҮН	3.4%	N/A	0.0%	10.0%	-14.9%	1.7x	1.1x	10.8x
Select Medical Holdings Corporation	SEM	3.9%	17.6%	3.4%	10.5%	8.1%	1.4x	1.4x	12.9x
	Г								
	Mean	5.3%	19.6%	3.9%	11.4%	-0.3%	121.3%	1.1x	9.9x


Valuation Metrics (cont.)

Return Profile, Trading Metrics

				Trading Multiples					
Company Name	Ticker	Return on Assets	Return on Equity	Revenue Growth	EBITDA Margin	EBITDA Growth	5-yr Beta	TEV / LTM Revenue	TEV / LTM EBITDA
Pharmaceuticals									
Eli Lilly and Company	ABBV	9.6%	54.8%	-5.6%	33.1%	-15.4%	0.3x	16.1x	48.7x
AbbVie Inc.	PFE	0.0%	0.0%	-2.3%	50.6%	-7.5%	0.5x	5.7x	11.3x
Merck & Co., Inc.	LLY	0.0%	0.0%	2.0%	21.5%	-46.6%	0.3x	4.9x	23.0x
Pfizer Inc.	MRK	11.6%	31.6%	0.6%	43.7%	9.1%	0.5x	2.3x	5.3x
Bristol-Myers Squibb Company	BMY	5.6%	24.7%	-4.2%	41.4%	-12.3%	0.4x	3.5x	8.5x
Perrigo Company plc	PRGO	1.2%	-2.6%	8.5%	12.2%	24.2%	0.8x	1.9x	15.6x
Amneal Pharmaceuticals, Inc.	AMRX	3.8%	-88.2%	8.3%	20.5%	9.5%	1.4x	1.3x	6.6x
	Mean	4.5%	2.9%	1.0%	31.9%	-5.6%	62.8%	5.1x	17.0x
Source: Capital IQ	Median	3.8%	0.0%	0.6%	33.1%	-7.5%	54.7%	3.5x	11.3x

LTM Equity Performance






Recent M&A Activity Last Twelve (12) Months as of June 30, 2023

(USD in millions)

Close Date	Target	Acquirer	Implied TEV
Dec-22	Abiomed, Inc.	Johnson & Johnson	\$18,157
Oct-22	Change Healthcare Inc.	Optum, Inc.	\$13,548
May-23	Oak Street Health, Inc.	CVS Health Corporation	\$10,467
Jun-23	Prometheus Biosciences, Inc.	Merck & Co., Inc.	\$10,163
Jan-23	City Practice Group of New York, LLC	Village Practice Management Company, LLC	\$8,900
Mar-23	Signify Health, Inc.	CVS Pharmacy, Inc.	\$7,817
Feb-23	LHC Group, Inc.	OptumHealth, Inc.	\$6,154
Oct-22	Global Blood Therapeutics, Inc.	Pfizer Inc.	\$5,364
Aug-22	Hospice and Personal Care Divisions of Kindred at Home	Clayton, Dubilier & Rice, LLC	\$4,667
Oct-22	Covetrus, Inc.	Clayton, Dubilier & Rice, LLC; TPG Capital, L.P.; TPG Global, LLC; TPG	\$4,183
Feb-23	1Life Healthcare, Inc.	Amazon.com, Inc.	\$4,008
Oct-22	ChemoCentryx, Inc.	Amgen Inc.	\$3,644
Aug-22	Affinivax, Inc.	GSK plc	\$3,300
Nov-22	Biosimilars Portfolio and Related Commercial and Operational Capabilities	of Biocon Biologics Limited	\$3,285
Aug-22	Turning Point Therapeutics, Inc.	Bristol-Myers Squibb Company	\$3,058
Apr-23	Provention Bio, Inc.	Sanofi	\$2,784
Mar-23	Applied, Food and Enterprise Services Businesses of PerkinElmer, Inc.	New Mountain Capital, L.L.C.	\$2,450
Jun-23	OneOncology, LLC	AmerisourceBergen Corporation; TPG Inc.	\$2,100
Mar-23	Immucor, Inc.	Werfen, S.A.	\$2,000
Jun-23	CTI BioPharma Corp.	Swedish Orphan Biovitrum AB (publ)	\$1,694
Jul-22	Sierra Oncology, Inc.	GlaxoSmithKline plc (nka:GSK plc)	\$1,657
Jul-22	Parata Systems, LLC	Becton, Dickinson and Company	\$1,548
Jan-23	Meridian Bioscience, Inc.	SD Biosensor, Inc; SJL Partners	\$1,481
Nov-22	Villaris Therapeutics, Inc.	Incyte Corporation	\$1,430
Jun-23	Heska Corporation	Antech Diagnostics, Inc.	\$1,419
Oct-22	Hanger, Inc.	Patient Square Capital, LP	\$1,373
Jul-22	PANTHERx Rare, LLC	Nautic Partners, LLC; General Atlantic Service Company, L.P.; The Vistria	\$1,373
Dec-22	Magellan Rx Management, LLC	Prime Therapeutics, LLC	\$1,350
Feb-23	Cerveau Technologies, Inc.	Lantheus Holdings, Inc.	\$1,310
Jul-22	Nutraceutical Wellness LLC	Unilever PLC	\$1,305


Change in Market Capitalization by Sector


Last Three (3) Months as of June 30, 2023



M&A Deal Flow Statistics

Last Three (3) Years as of June 30, 2023





7 Houlihan Capital About Us

Houlihan Capital is a leading, solutions-driven valuation, financial advisory and investment banking firm. We pride ourselves on being thought leaders in an ever-changing landscape.

Houlihan Capital is SOC-compliant, a FINRA and SIPC member and committed to the highest levels of professional ethics and standards.

Valuation & Financial Advisory

- Portfolio Valuation (ASC 820)
- Complex & Illiquid Securities (Level 3)
- Cryptoasset /Blockchain Valuations
 - o Locked Token Valuations
- Enterprise Valuations
- Fairness & Solvency Opinions
 - o SPAC Fairness
- Estate & Gift Valuations
- Purchase Price Allocation (ASC 805)
- Goodwill Impairment Testing (ASC 350)
- Stock-based Compensation (ASC 718, IRC 409A)

Investment Banking

- Mergers & Acquisitions
 - o Sell-Side Advisory
 - o Sale of Minority Ownership Positions
 - o Leveraged Buyouts
 - o Majority Recapitalizations
 - o Corporate Divestitures
- Corporate Financial Services
 - Financial Modeling
 - Investor Presentation
 - Valuation Analysis
 - Strategic Advisory

For questions or inquiries regarding our services, please contact:

info@houlihancapital.com